This is a working overview of prohibited list, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-02. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Cryopreservation of whole moss plants, especially Physcomitrella patens, has been developed by Ralf Reski and coworkers and is performed at the International Moss Stock Center. This biobank collects, preserves, and distributes moss mutants and moss ecotypes.
Dietary restrictions are not used by the highly urban Brazilian ayahuasca church União do Vegetal, suggesting the risk is much lower than perceived and probably non-existent. The ritual use of ayahuasca by the Achuar people is featured in the Bruce Parry 2008 documentary series Amazon, in which Parry participates in the rite.
In 2023, world production of peppermint was 35,547 tonnes, led by Morocco with 78% of the total and Argentina with 20% (table). In 2020, Oregon and Washington produced most of American peppermint, the leaves of which are processed for the essential oil to produce flavourings mainly for chewing gum and toothpaste.
Sources: en.wikipedia.org
autoignition temperature Also kindling point. The lowest temperature at which a given substance will spontaneously ignite in a normal atmosphere without an external source of ignition such as a flame or spark, i.e. when the ambient temperature is sufficiently high to provide the activation energy needed for combustion. Substances which spontaneously ignite at naturally occurring temperatures are termed pyrophoric. Compare ignition temperature.
Chaplain, University of Sunderland. For services to Higher Education. Dr Catherine Marian Hubbert. Macmillan General Practitioner and Founder, Woodlands Hospice Charitable Trust. For services to Palliative Care. Antony Jasper Hudgell. Co-Founder, Tony Hudgell Foundation. For services to the Prevention of Child Abuse. Karen Humphries. Assessor and Duke of Edinburgh Award Manager, Nunnery Wood High School, Worcester. For services to Young People. Graham Walter Hundley. Emergency Response Volunteer, Cumbria. For voluntary service to the British Red Cross. Elaine Hutchings. For services to the community in Lichfield, Staffordshire during Covid-19. Lena Moira Hutchinson. For voluntary services to the community in Larne, County Antrim. William David Hutton. Founder, Campsie Accordion and Fiddle Club. For services to Music and to the community in Dunbartonshire. Robert Alan John Illman. For services to Mountain Rescue in Dartmoor, Devon. Richard Stansfield Isaac. Community and Sustainability Manager, Northern Trains. For services to Inclusion in the Rail Industry. Clive Herbert Jackson. For services to the community in York. Christopher Angus Jamieson. Special Inspector, British Transport Police (Scotland). For services to Policing. Patricia Carol Jarman. For services to the community in Stalybridge, Metropolitan Borough of Tameside. Michael George Jaynes. Akela, 1st Hatherley Scouts, Cheltenham. For services to Young People and to the community in Cheltenham, Gloucestershire. Hilary Mary Jenkins. For services to the community in Wiltshire, particularly during Covid-19.
== International Organization for Standardization (ISO) == CLSI participates in the development of international standards as the Secretariat of ISO Technical Committee (TC) 212, clinical laboratory testing and in vitro diagnostic test systems. This responsibility was delegated to CLSI by the American National Standards Institute (ANSI), an ISO member body. CLSI also serves as the administrator for the US Technical Advisory Committee (TAG) for ISO/TC 212.
Hydromorphone is a semi-synthetic μ-opioid agonist. As a hydrogenated ketone of morphine, it shares the pharmacologic properties typical of opioid analgesics. Hydromorphone and related opioids produce their major effects on the central nervous system and gastrointestinal tract. These include analgesia, drowsiness, mental clouding, changes in mood, euphoria or dysphoria, respiratory depression, cough suppression, decreased gastrointestinal motility, nausea, vomiting, increased cerebrospinal fluid pressure, increased biliary pressure, and increased pinpoint constriction of the pupils.
Sources: en.wikipedia.org
persons and nationals." On March 6, 2026, Anthropic's CEO Dario Amodei stated that his company will challenge the DoD in court. Anthropic's partners, including Microsoft, Amazon and Google stated their agreement with Amodei. On March 8, 2026, OpenAI (the parent company of ChatGPT) announced that their head of robotics, Caitlin Kalinowski, had resigned stating, "surveillance of Americans without judicial oversight and lethal autonomy without human authorization are lines that deserved more deliberation than they got."
Depending on the species, an adult earthworm can be from 10 mm (0.39 in) long and 1 mm (0.039 in) wide to 3 m (9.8 ft) long and over 25 mm (0.98 in) wide, but the typical Lumbricus terrestris grows to about 360 mm (14 in) long. Probably the longest worm on confirmed records is Amynthas mekongianus that extends up to 3 m (10 ft) in the mud along the banks of the 4,350 km (2,700 mi) Mekong River in Southeast Asia. From front to back, the basic shape of the earthworm is a cylindrical tube-in-a-tube, divided into a series of segments (called metameres) that compartmentalize the body. Furrows are generally externally visible on the body demarking the segments. Dorsal pores and nephridiopores exude a fluid that moistens and protects the worm's surface, also allowing it to breathe. Except for the mouth and anal segments, each segment carries bristlelike hairs called lateral setae used to anchor parts of the body during movement. Species may have four pairs of setae on each segment or more than eight sometimes forming a complete circle of setae per segment. Special ventral setae are used to anchor mating earthworms by their penetration into the bodies of their mates. Generally, within a species, the number of segments found is consistent across specimens, and individuals are born with the number of segments they will have throughout their lives, growth in size being by enlarging existing segments rather than by adding new ones.
AMP + diphosphate + GMP + L-glutamate The 4 substrates of this enzyme are ATP, xanthosine 5'-phosphate, L-glutamine, and H2O, whereas its 4 products are AMP, diphosphate, GMP, and L-glutamate. This enzyme belongs to the family of ligases, specifically those forming carbon-nitrogen bonds carbon-nitrogen ligases with glutamine as amido-N-donor. The systematic name of this enzyme class is xanthosine-5'-phosphate:L-glutamine amido-ligase (AMP-forming). This enzyme participates in purine metabolism and glutamate metabolism. At least one compound, Psicofuranin is known to inhibit this enzyme.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.